Robert O. Blaustein

2.5k total citations · 1 hit paper
51 papers, 1.7k citations indexed

About

Robert O. Blaustein is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Robert O. Blaustein has authored 51 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Cardiology and Cardiovascular Medicine, 18 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in Robert O. Blaustein's work include Heart Failure Treatment and Management (22 papers), Cardiovascular Function and Risk Factors (18 papers) and Cardiac pacing and defibrillation studies (13 papers). Robert O. Blaustein is often cited by papers focused on Heart Failure Treatment and Management (22 papers), Cardiovascular Function and Risk Factors (18 papers) and Cardiac pacing and defibrillation studies (13 papers). Robert O. Blaustein collaborates with scholars based in United States, Canada and Germany. Robert O. Blaustein's co-authors include Alexei V. Finkelstein, Jonathan A. Javitch, Solomon H. Snyder, R. John Collier, T M Koehler, Alan Finkelstein, Christopher Miller, Bibhuti R. DasGupta, Philip A. Cole and Carole Williams and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Circulation.

In The Last Decade

Robert O. Blaustein

49 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction

2020 184 citations Paul W. Armstrong, Carolyn S.P. Lam et al. JAMA profile →

Peers

Robert O. Blaustein

CCM

CMN

GENET

IMMUN

Xiaoping Liu China

Richard H. Ashley United Kingdom

Virendra K. Sharma United States

Amanda Kovach Hungary

Graham J. Moore Canada

Christopher H. George United Kingdom

P. Schelling Germany

Joaquín Fernández‐Irigoyen Spain

Miyuki Kuno Japan

Varsha G. Desai United States

Xiaoping Liu China

Robert O. Blaustein

1.1k ×1.2

237 ×0.5

CCM

228 ×0.5

CMN

120 ×0.4

GENET

116 ×0.7

IMMUN

Citations per year, relative to Robert O. Blaustein Robert O. Blaustein (= 1×) peers Xiaoping Liu

Countries citing papers authored by Robert O. Blaustein

Since Specialization

Citations

This map shows the geographic impact of Robert O. Blaustein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert O. Blaustein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert O. Blaustein more than expected).

Fields of papers citing papers by Robert O. Blaustein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert O. Blaustein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert O. Blaustein. The network helps show where Robert O. Blaustein may publish in the future.

Co-authorship network of co-authors of Robert O. Blaustein

This figure shows the co-authorship network connecting the top 25 collaborators of Robert O. Blaustein. A scholar is included among the top collaborators of Robert O. Blaustein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert O. Blaustein. Robert O. Blaustein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Greene, Stephen J., Hanna K. Gaggin, Lori D. Bash, et al.. (2025). Cardiologist-Reported Reasons for Not Titrating Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction. Journal of Cardiac Failure. 31(8). 1365–1369.

Reddy, Yogesh N.V., Javed Butler, Kevin J. Anstrom, et al.. (2024). Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial. European Journal of Heart Failure. 27(2). 209–218. 8 indexed citations

Greene, Stephen J., Hanna K. Gaggin, Mo Zhou, et al.. (2024). Treatment Patterns of Patients with Worsening Heart Failure with Reduced Ejection Fraction. ESC Heart Failure. 11(4). 1932–1946. 3 indexed citations

Yogasundaram, Haran, Yinggan Zheng, Justin A. Ezekowitz, et al.. (2023). Relationship Between Baseline Electrocardiographic Measurements and Outcomes in Patients with High-Risk Heart Failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) Trial. European Journal of Heart Failure. 25(10). 1822–1830. 3 indexed citations

Kaul, Padma, Carolyn S.P. Lam, Cynthia M. Westerhout, et al.. (2023). Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction. JACC Heart Failure. 11(4). 392–403. 11 indexed citations

Butler, Javed, Muhammad Shahzeb Khan, Tomasz Gąsior, et al.. (2023). Accelerometer vs. Other Activity Measures in Heart Failure with Preserved Ejection Fraction: The VITALITY-HFpEF Trial. ESC Heart Failure. 11(1). 293–298. 5 indexed citations

Armstrong, Paul W., Yinggan Zheng, Lars H. Lund, et al.. (2023). Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat. Circulation Heart Failure. 16(10). e010661–e010661.

Himmel, Herbert M., et al.. (2023). Nonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat. Journal of Pharmacology and Experimental Therapeutics. 386(1). 26–34. 4 indexed citations

Armstrong, Paul W., Carolyn S.P. Lam, Kevin J. Anstrom, et al.. (2020). Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. JAMA. 324(15). 1512–1512. 184 indexed citations breakdown →

10.

Goren, Emily, Li‐An Lin, Robert O. Blaustein, & Greg Ball. (2020). Bayesian Meta-analysis of Safety Outcomes Using Blinded Clinical Trial Data. Therapeutic Innovation & Regulatory Science. 54(6). 1557–1565. 6 indexed citations

11.

Johns, Douglas G., Mihajlo L. Krsmanovic, Min Lu, et al.. (2018). Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes. Drug Metabolism and Disposition. 47(3). 227–233. 5 indexed citations

12.

Teramoto, Tamio, Hiroyuki Daida, Katsunori Ikewaki, et al.. (2017). Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia. Atherosclerosis. 261. 69–77. 9 indexed citations

13.

Arai, Hidenori, Tamio Teramoto, Hiroyuki Daida, et al.. (2016). Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 249. 215–223. 10 indexed citations

14.

Webb, Nicholas J.A., Thomas G. Wells, Shahnaz Shahinfar, et al.. (2014). A Randomized, Open-Label, Dose-Response Study of Losartan in Hypertensive Children. Clinical Journal of the American Society of Nephrology. 9(8). 1441–1448. 16 indexed citations

15.

Anderson, Damon S. & Robert O. Blaustein. (2008). Preventing Voltage-dependent Gating of Anthrax Toxin Channels Using Engineered Disulfides. The Journal of General Physiology. 132(3). 351–360. 12 indexed citations

16.

Blaustein, Robert O.. (2002). Kinetics of Tethering Quaternary Ammonium Compounds to K+ Channels. The Journal of General Physiology. 120(2). 203–216. 17 indexed citations

17.

Blaustein, Robert O. & Alexei V. Finkelstein. (1990). Voltage-dependent block of anthrax toxin channels in planar phospholipid bilayer membranes by symmetric tetraalkylammonium ions. Effects on macroscopic conductance.. The Journal of General Physiology. 96(5). 905–919. 71 indexed citations

18.

Blaustein, Robert O. & Alexei V. Finkelstein. (1990). Diffusion limitation in the block by symmetric tetraalkylammonium ions of anthrax toxin channels in planar phospholipid bilayer membranes.. The Journal of General Physiology. 96(5). 943–957. 38 indexed citations

19.

Blaustein, Robert O. & Alan Finkelstein. (1988). A hydroxide ion carrier in planar phospholipid bilayer membranes: (C6F5)2Hg (dipentafluorophenylmercury). Biochimica et Biophysica Acta (BBA) - Biomembranes. 946(2). 221–226. 6 indexed citations

20.

Blaustein, Robert O., et al.. (1987). The N‐terminal half of the heavy chain of botulinum type A neurotoxin forms channels in planar phospholipid bilayers. FEBS Letters. 226(1). 115–120. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact